港交所(00388.HK)推出六隻新股票期貨合約及六隻期權類別 明年1月10日登場
港交所(00388.HK)宣佈,將於2022年1月10日推出六隻新的股票期貨合約及六隻新的股票期權類別,相關股票爲信義玻璃(00868.HK)、信義光能(00968.HK)、贛鋒鋰業(01772.HK)、中遠海控(01919.HK)、李寧(02331.HK)、洛陽鉬業(03993.HK)。新股票期貨合約首六個月的證監會徵費將可獲得豁免。
港交所今年首十一個月股票期貨及股票期權分別錄得約224.3萬張合約及約1.48億張合約的成交量,較去年全年成交量增加96%及13%,並創出紀錄新高。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.